Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Podobne zapisy

• Comparison of immune modulation by TLR8 agonist vtx-2337 (motolimod) in cancer patients and healthy volunteers
  od: Dietsch, Greg, i wsp.
  Wydane: (2014)
• TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
  od: Lu, Hailing, i wsp.
  Wydane: (2013)
• Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
  od: Dietsch, Gregory N., i wsp.
  Wydane: (2016)
• The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
  od: Cheng, Yinwen, i wsp.
  Wydane: (2021)
• VTX‐1463, a novel TLR‐8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs
  od: Royer, Christopher M., i wsp.
  Wydane: (2015)